CMET-22. INTRATHECAL (IT) TRAZTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY

Pts with HER2+ breast cancer have frequent LM. No current FDA approvals exist. A multicenter phase I/II trial assessing safety and efficacy of IT T in LM pts was conducted. The primary endpoint in phase 2 was response rate (RR). Complete response (CR) required cytologic CR (CCR) + radiographic CR (R...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Kumthekar, Priya, Gradishar, William, Lin, Nancy, Pentsova, Elena, Groves, Morris, Jeyapalan, Suriya, Melisko, Michelle, Grimm, Sean, B. Lassman, Andrew, Raizer, Jeffrey
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216912/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.234
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars